The autocrine effects of the SHH pathway have previously been linked to cellular proliferation in NSCLC cell lines (A549, H322M, and HOP-62) and solid lung carcinomas derived from patients; specifically, GLI-1 genetic silencing combined with an SHH antagonist reduces lung tumor cellular proliferation [29]. The gene discussed is GLI1; the disease is non-small cell lung carcinoma.